NEW YORK – If Merck is successful in garnering US Food and Drug Administration approval for pembrolizumab (Keytruda) in advanced cancer patients with high tumor mutational burden, it will be the second pan-cancer indication for the drug.
This will allow Merck, which recorded pembrolizumab sales of $11.1 billion last year, to make the drug available to more cancer patients who are out of treatment options.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
